Eli Lilly Aktie: Novo schlägt zurück
Kubient stock: Former CEO sentenced over $1.3 million fraud
Jaguar Health stock: Crofelemer program targets 2027 MVID filing
Tango Therapeutics Aktie: Kombi-Studie startet
Fulton Financial stock: Q3 profit reaches USD 114.1 million
Nokia Aktie: Hotwire-Auftrag fĂĽr Netz in North Carolina
International Bancshares stock heads into key third-quarter report
Great Southern Bancorp stock: Q3 hit by hedge charge
GE HealthCare stock raises 2026 outlook after Q3 beat
elf Beauty Aktie: Prognose nach oben gehievert
Gap stock enters November 19 earnings report at EUR 21.15
Evonik Draws a Line at Talks With BASF While Analysts Reward Earnings, Not the Stock
AMD's AI Boom Comes With a Price Tag Wall Street Is Still Calculating
Forestar stock faces lower profit and fiscal 2027 targets
Vulcan Energy's Funding Wins Don't Settle the Lithium Question
Allianz Rides Post-Midterm Rotation as Investors Weigh Hype Against Hard Numbers
Equitable Holdings stock gains as Q3 operating EPS rises 19%
UnitedHealth Group Aktie: Dividende beschlossen, Auszahlung am 15. Dezember
LPKF Laser Aktie: Bereinigtes EBIT bleibt negativ
AeroVironment Aktie: Stifel senkt Kursziel nach SCAR-Aus
50-30-20-Regel: So teilen Sie Ihr Einkommen fĂĽr Ausgaben und RĂĽcklagen auf
Gates Industrial stock gets new belt product for industrial buyers
Invesque stock heads toward a go-private transaction with Magnetar
GeForce 621.14 WHQL: NVIDIA behebt Bildausfälle bei RTX 50 und RTX Spark
GitLab stock in focus after GitLab Orbit reaches general availability
Iovance Aktie: Q3-Zahlen mĂĽssen Prognose stĂĽtzen
Hensoldt Aktie: Kapitalmarkttag in London soll Logistikfragen klären
Dogwood Therapeutics stock enters November with Phase 2b focus
Bewegung gegen Depression: Schon 75 Minuten pro Woche zeigen messbare Vorteile
HubSpot Aktie: Prognose enttäuscht trotz Rekordquartal
H&R Block stock in focus ahead of fiscal 2027 results
BYD's Autonomous Bus Debut Arrives as Investors Wait on Earnings Proof
Evotec's Nine-Month Beat Meets a Halved Target and a Trimmed JPMorgan Stake
BioNTech's Pipeline Faces Its Reckoning as Trial Data Cut Both Ways